CO2021011188A2 - Compuesto heterocíclico y su uso - Google Patents
Compuesto heterocíclico y su usoInfo
- Publication number
- CO2021011188A2 CO2021011188A2 CONC2021/0011188A CO2021011188A CO2021011188A2 CO 2021011188 A2 CO2021011188 A2 CO 2021011188A2 CO 2021011188 A CO2021011188 A CO 2021011188A CO 2021011188 A2 CO2021011188 A2 CO 2021011188A2
- Authority
- CO
- Colombia
- Prior art keywords
- heterocyclic compound
- receptor agonist
- activity
- orexin type
- narcolepsy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
RESUMEN La presente proporciona un compuesto heterocíclico que tiene actividad de un agonista del receptor de orexina tipo 2. Un compuesto representado por la fórmula (I): en donde cada símbolo es como se describe en la memoria descriptiva, o una de sus sales tiene una actividad del agonista del receptor de orexina tipo 2, y es útil como un agente para la profilaxis o tratamiento de la narcolepsia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019015488 | 2019-01-31 | ||
PCT/JP2020/004444 WO2020158958A1 (en) | 2019-01-31 | 2020-01-30 | Heterocyclic compound and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021011188A2 true CO2021011188A2 (es) | 2021-10-29 |
Family
ID=69770989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0011188A CO2021011188A2 (es) | 2019-01-31 | 2021-08-25 | Compuesto heterocíclico y su uso |
Country Status (20)
Country | Link |
---|---|
US (3) | US11028048B2 (es) |
EP (1) | EP3917616A1 (es) |
JP (2) | JP7253640B2 (es) |
KR (1) | KR20210121080A (es) |
CN (1) | CN113395993B (es) |
AR (1) | AR117916A1 (es) |
AU (1) | AU2020215380A1 (es) |
BR (1) | BR112021014180A2 (es) |
CA (1) | CA3124536A1 (es) |
CL (1) | CL2021001973A1 (es) |
CO (1) | CO2021011188A2 (es) |
EA (1) | EA202192138A1 (es) |
EC (1) | ECSP21056325A (es) |
IL (1) | IL284073A (es) |
MX (1) | MX2021008241A (es) |
PE (1) | PE20211700A1 (es) |
SG (1) | SG11202106791XA (es) |
TW (1) | TWI832962B (es) |
WO (1) | WO2020158958A1 (es) |
ZA (1) | ZA202106304B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023502441A (ja) | 2019-11-25 | 2023-01-24 | アルカームス インコーポレーテッド | 置換大環状化合物および関連する治療方法 |
EP4066893A4 (en) | 2019-11-27 | 2023-12-20 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
CR20230089A (es) | 2020-08-18 | 2023-04-11 | Merck Sharp & Dohme Llc | Agonistas de bicicloheptano pirrolidina de los receptores de orexina |
US20230271973A1 (en) * | 2020-09-03 | 2023-08-31 | Orexia Therapeutics Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
US20230331720A1 (en) * | 2020-09-03 | 2023-10-19 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
CA3215906A1 (en) | 2021-04-02 | 2022-10-06 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for post operation recovery |
WO2022207935A1 (en) * | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
WO2023167925A1 (en) | 2022-03-01 | 2023-09-07 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
WO2023199091A1 (en) | 2022-04-12 | 2023-10-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
EP1196609A2 (en) | 1999-06-28 | 2002-04-17 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
EP1252329A4 (en) | 1999-07-30 | 2004-12-22 | Univ Leland Stanford Junior | HYPOCRETINE AND HYPOCRETINE RECEPTORS FOR THE REGULATION OF SLEEP AND SLEEP DISORDERS |
US7112566B1 (en) | 1999-09-17 | 2006-09-26 | The Regents Of The University Of California | Systemic administration of Hypocretin-1 |
US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
WO2001074162A1 (en) | 2000-04-04 | 2001-10-11 | The Regents Of The University Of California | Treatment of sleep disorders with hypocretin-1 |
US20060134109A1 (en) | 2002-09-09 | 2006-06-22 | Nura Inc. | G protein coupled receptors and uses thereof |
US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
JP2006518709A (ja) | 2002-12-13 | 2006-08-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒトオレキシン−2受容体のモジュレーターを同定する方法 |
HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
MX2008013114A (es) | 2006-04-14 | 2008-10-21 | Abbott Gmbh & Co Kg | Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3. |
AU2012200270A1 (en) * | 2007-05-23 | 2012-02-09 | Merck Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
WO2009049215A1 (en) | 2007-10-10 | 2009-04-16 | Wake Forest University Health Sciences | Methods to reduce the effects of sleep deprivation |
US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
EP2694472B1 (en) * | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
TW201341380A (zh) * | 2012-04-05 | 2013-10-16 | Takeda Pharmaceutical | 磺醯胺衍生物及其用途 |
AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
WO2014170343A1 (en) | 2013-04-15 | 2014-10-23 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders |
WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
WO2015048091A1 (en) | 2013-09-24 | 2015-04-02 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
EP3068783B1 (en) | 2013-11-15 | 2020-09-23 | The Board of Trustees of the Leland Stanford Junior University | Agonists of hypocretin receptor 2 for use for treating heart failure |
MX2016007661A (es) | 2013-12-12 | 2017-01-06 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo. |
JP6552117B2 (ja) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | 敗血症の予防治療剤 |
WO2016025669A1 (en) * | 2014-08-13 | 2016-02-18 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
EP3029024A1 (en) | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
WO2016133160A1 (ja) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
WO2016199906A1 (ja) | 2015-06-12 | 2016-12-15 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
US10980755B2 (en) | 2015-09-10 | 2021-04-20 | The Regents Of The University Of California | LRH-1 modulators |
US10508083B2 (en) * | 2016-02-04 | 2019-12-17 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
EP3594202B1 (en) | 2017-03-08 | 2021-08-11 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
EP3663281B1 (en) | 2017-08-03 | 2022-12-28 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
JPWO2019112007A1 (ja) | 2017-12-07 | 2020-12-24 | 国立大学法人 筑波大学 | 鎮痛薬による眠気の予防または治療薬 |
WO2020004537A1 (ja) | 2018-06-29 | 2020-01-02 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP3816154A4 (en) | 2018-06-29 | 2022-03-30 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF |
US20220017514A1 (en) | 2018-12-12 | 2022-01-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20230042358A1 (en) | 2018-12-12 | 2023-02-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2020
- 2020-01-30 JP JP2021568451A patent/JP7253640B2/ja active Active
- 2020-01-30 AU AU2020215380A patent/AU2020215380A1/en active Pending
- 2020-01-30 US US16/777,273 patent/US11028048B2/en active Active
- 2020-01-30 CA CA3124536A patent/CA3124536A1/en active Pending
- 2020-01-30 TW TW109102825A patent/TWI832962B/zh active
- 2020-01-30 AR ARP200100236A patent/AR117916A1/es unknown
- 2020-01-30 EP EP20709748.6A patent/EP3917616A1/en active Pending
- 2020-01-30 CN CN202080011417.1A patent/CN113395993B/zh active Active
- 2020-01-30 WO PCT/JP2020/004444 patent/WO2020158958A1/en unknown
- 2020-01-30 US US17/427,490 patent/US20230040770A1/en not_active Abandoned
- 2020-01-30 MX MX2021008241A patent/MX2021008241A/es unknown
- 2020-01-30 BR BR112021014180-4A patent/BR112021014180A2/pt unknown
- 2020-01-30 EA EA202192138A patent/EA202192138A1/ru unknown
- 2020-01-30 PE PE2021001139A patent/PE20211700A1/es unknown
- 2020-01-30 SG SG11202106791XA patent/SG11202106791XA/en unknown
- 2020-01-30 KR KR1020217024931A patent/KR20210121080A/ko unknown
-
2021
- 2021-04-23 US US17/239,191 patent/US20210276949A1/en not_active Abandoned
- 2021-06-16 IL IL284073A patent/IL284073A/en unknown
- 2021-07-27 CL CL2021001973A patent/CL2021001973A1/es unknown
- 2021-07-30 EC ECSENADI202156325A patent/ECSP21056325A/es unknown
- 2021-08-25 CO CONC2021/0011188A patent/CO2021011188A2/es unknown
- 2021-08-30 ZA ZA2021/06304A patent/ZA202106304B/en unknown
-
2023
- 2023-03-27 JP JP2023050325A patent/JP2023078426A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200247747A1 (en) | 2020-08-06 |
US20230040770A1 (en) | 2023-02-09 |
US11028048B2 (en) | 2021-06-08 |
BR112021014180A2 (pt) | 2021-09-21 |
CN113395993A (zh) | 2021-09-14 |
ECSP21056325A (es) | 2021-09-30 |
TW202043196A (zh) | 2020-12-01 |
US20210276949A1 (en) | 2021-09-09 |
CL2021001973A1 (es) | 2022-04-08 |
AR117916A1 (es) | 2021-09-01 |
EP3917616A1 (en) | 2021-12-08 |
JP2022519331A (ja) | 2022-03-22 |
TWI832962B (zh) | 2024-02-21 |
PE20211700A1 (es) | 2021-09-01 |
AU2020215380A1 (en) | 2021-08-19 |
ZA202106304B (en) | 2023-06-28 |
CN113395993B (zh) | 2024-02-20 |
IL284073A (en) | 2021-08-31 |
KR20210121080A (ko) | 2021-10-07 |
JP7253640B2 (ja) | 2023-04-06 |
WO2020158958A1 (en) | 2020-08-06 |
MX2021008241A (es) | 2021-08-16 |
SG11202106791XA (en) | 2021-07-29 |
AU2020215380A2 (en) | 2021-08-19 |
JP2023078426A (ja) | 2023-06-06 |
EA202192138A1 (ru) | 2022-03-10 |
CA3124536A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021011188A2 (es) | Compuesto heterocíclico y su uso | |
CL2020000272A1 (es) | Compuesto heterocíclico y su uso. | |
CO2018008705A2 (es) | Compuestos de piperidina sustituido y su uso | |
UY37494A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
UY31781A (es) | Derivados de iminopiridina y su uso | |
CO6491037A2 (es) | Derivados de pirazinooxazepina | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
CL2019002662A1 (es) | Inhibidores de ip6k. | |
CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
CL2022003666A1 (es) | Compuestos de piperidina sustituida y su uso. | |
BR112022010323A2 (pt) | Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal | |
AR070874A1 (es) | Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer. | |
CL2021001246A1 (es) | Moduladores de expresión irf5. | |
CO2020003134A2 (es) | Moduladores de la expresión de enac | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
AR102053A1 (es) | Eliminación de dióxido de carbono de una corriente de fluido | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
AR109406A1 (es) | Compuesto de 1-fenil-3-carbamoilurea y su uso | |
CO2019012270A2 (es) | Compuesto heterocíclico | |
AR109405A1 (es) | Compuestos de fenilurea y su uso | |
BR112018072255A2 (pt) | azasteroides para tratamento de tuberculose | |
CO2019012295A2 (es) | Compuesto heterocíclico | |
AR117079A1 (es) | Moduladores de la expresión de foxp3 | |
CO2020012101A2 (es) | Compuesto heterocíclico |